By Aditya Kalra and Paritosh Bansal NEW DELHI (Reuters) – Drugmaker Abbott Healthcare is challenging an Indian state’s accusation that a sample of the company’s cough syrup contained excessive levels of codeine, the second multinational to question India’s regulatory testing regime in recent months. Whether the sample of Abbott’s popular “Phensedyl” was a genuine product or a fake has not been established, but the suspect batch of 80,000 bottles has not been recalled. The state laboratory in West Bengal first raised the alarm last November.
See the rest here:
Exclusive: Abbott tangles with regulators over Indian cough syrup complaint